Effective at improving revenue, team productivity and policies to keep the facility operating at a sustainable and profitable level. Well-versed in motivating and retaining employees, building relationships with patients health insurances and vendors and families and achieving the requirements for continued accreditation. Passionate professional able to adapt quickly to new and changing environments. Natural capacity to lead or contribute to a team. Impeccable work ethic and success in developing a diverse client base.
|
|
· Clinical Protocol FX006-2018-016: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis.
· Clinical Protocol A7005: PRO Study: A Study to Characterize Real-World Clinical Outcomes of Spinal Cord Stimulation (SCS) Using Retrospective Review of De-Identified Patient Records.
· Clinical Protocol 1237-0064: Randomization Pragmatic Clinical Trial in a Community Based Setting Comparing Stiolto Respimat vs. ICS-Laba Plus Lama in Patients with COPD
· Clinical Protocol A7007: ENVISION Study: A Study to Characterize the Relationship Between Selective Metrics and Clinical Outcomes in Chronic Pain Patients Treated with Boston Scientific Commercially Approved Neurostimulations Systems and may use Observed Relationships to make Recommendations
· Clinical Protocol AXS-07-301: A Randomized, Double-blind, Single-dose, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-07 (meloxicam and rizatriptan) for the Acute Treatment of Migraine in Adults
· Clinical Protocol A4070: Study to Demonstrate the Value of Multiple Modalities and Combining Mechanisms using the Spectra WaveWriter Spinal Cord Stimulator System in the Treatment of Chronic Pain
· Clinical Protocol 2015-DFU-301: A Phase 3, Randomized, Double-blind, Parallel-group, Vehicle controlled, Multicenter Study of the Efficacy and Safety of Granexin Gel in the Treatment of Diabetic Foot Ulcer
· Clinical Protocol 6603/1133: A Multicenter, Randomized, Double-blind, Cham-controlled, Comparative Study of SI-6603 in Subjects with Lumbar Disc Herniation (Phase 3)
· Clinical Protocol RPC01-3202: Induction Study #2: A Phase 3 Multicenter Randomized, Double -Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease.
· Clinical Protocol RPC01-3203: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease.
· Clinical Protocol RPC01-3204: A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease.
· Clinical Protocol M16-006: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease
· Clinical Protocol M15-991: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
· Clinical Protocol M16-000: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991
· Clinical Protocol M16-066: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065.
· Clinical Protocol M16-067: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy.
· Clinical Protocol SKK 6603/1133: A Multicenter, Randomized, Double-blind, Sham-controlled, Comparative Study of SI-6603 in Subjects with Lumbar Disc Herniation (Phase 3).
· Clinical Protocol AXS02-301 CREATE-1 Sub- Study: CRPS Treatment Evaluation 1 Study A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects.
· Clinical Protocol KF7013-04: Placebo-controlled efficacy and safety trial of intravenous neridronic acid in subjects with complex regional pain syndrome (CRPS)
· Clinical Protocol IBD-600: Corrona Inflammatory Bowel Disease Registry
· Clinical Protocol UCB RA0098 / PXL # 225110: A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use Of An Electro-Mechanical Injection Device (E-Device) For The Subcutaneous Self-Injection Of Certolizumab Pegol Solution by Subjects with Moderate To Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Asthritis, or Moderately to Severely Active Crohn's Disease.
· BWH1-12-468: A randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome
· Clinical Protocol A7007: NAVITAS Study: A Study to Evaluate the Effect of Boston Relief SCS Systems on Auxiliary Objective Metrics for Pain. (A sub-study of the Boston RELIEF sub-study).
· Clinical Protocol AXS02-K301: A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS02 (Disodium Zoledronate Tetrahydate) Administered Orally to Subjects with Knee Osteoarthritis Associated with Bone Marrow Lesions.
· Clinical Protocol MTV-601-3001: Liberty 1- An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered with and without Low-Dose Estradiol and Norethindrone Acetate in Women and Heavy Menstrual Bleeding Associated with Uterine Fibroids.
· Clinical Protocol MVT-601-3101: SPIRIT 1 - An International Phase 3 Randomized, Double-Blind, Placebo Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Acetate in Women with Endometriosis-Associated Pain
· Clinical Protocol A7007: Boston RELIEF Study: A Global Registry to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain.
· Clinical Protocol CR 845-CLIN-3001: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study Evaluating The Analgesic Efficacy & Safety of Intravenous CR-845 In Patients Undergoing Abdominal Surgery.
· Clinical Protocol KF7013-03: Open-Label Safety Trial of Intravenous Neridronic Acid in Subjects with Complex Regional Pain Syndrome (CRPS)
· Clinical Protocol AXSO2-301: CREATE-1 Study CRPS Treatment Evaluation 1 Study A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects with Complex Regional Pain Syndrome Type 1 (CRPS-1)
· Clinical Protocol INN-CB-014: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the Xaracoll Bupivacaine Implant (300mg Bupivacaine Hydrochloride) After Open Laparotomy Hernioplasty
· Clinical Protocol INN-TOP-004: A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination with Systemic Antibiotic Therapy in Diabetic Patients with an Infected Foot Ulcer
· Clinical Protocol 6603/1132: A Multicenter, Open-Label Study of SI-6603 in Patients with Lumbar Disc Herniation. (Phase III)
· Clinical Protocol 6603/1131: A Multicenter, Randomized, Double-blind, Controlled, Comparative Study of SI-6603 in Patients with Lumbar Disc Herniation (Phase III)
· Clinical Protocol KF7013-01: A Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Intravenous Neridronic Acid in Subjects with Complex Regional Pain Syndrome Type I (CRPS-I)
· Clinical Protocol AMG334: A Prospective, Observational Study for the Psychometric Evaluation of a Novel Migraine-Related Functional Impact Instrument in Episodic and Chronic Migraines.
Resumes, and other information uploaded or provided by the user, are considered User Content governed by our Terms & Conditions. As such, it is not owned by us, and it is the user who retains ownership over such content.
School Attended
Job Titles Held:
Degrees
© 2021, Bold Limited. All rights reserved.